Market Overview

Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG

Share:
Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG
Related BLUE
Benzinga's Bulls And Bears For The Past Week: Disney, GE, Tesla And More
Breaking Down Barclays' New Bullish Calls On Biotech
Related CELG
Benzinga's Top Upgrades, Downgrades For September 15, 2017
Wall Street's M&A Chatter From September 14: Juno, Mallinckrodt, Cornerstone OnDemand

After market close on Wednesday, bluebird bio Inc (NASDAQ: BLUE) released early data on the relapsed/refractory multiple myeloma study. Traders flocked to the stock after the good news, and the stock was up 22 percent after hours, spiking to $74.45 at market open Thursday, before leveling out at $71.40 mid day.

BTIG Still Says Buy

Following a conference call hosted Thursday morning to discuss the results, BTIG Equity Research analyst Dana Leone published a note maintaining the earlier stated Buy rating and $83 price target on the stock, while highlighting that the dataset hints at a bluebird and Celgene Corporation (NASDAQ: CELG) combo having an “X-factor” in manufacturing CAR T products.

In an earlier published note, the analyst highlights the strong efficacy and low toxicity points demonstrated by the early data with no obvious patient differences when compared with competitor data.

“As a result, we do think the know-how of Celgene manufacturing combined with the lentiviral tech transfer from BLUE may be an X factor supporting initially superior results versus the competition,” said Leone.

At time of writing, bluebird shares were trading up around 18 percent at $71.16.

Image Credit: By WitcherGeralt (Own work) [CC BY-SA 3.0], via Wikimedia Commons

Latest Ratings for BLUE

DateFirmActionFromTo
Sep 2017BarclaysInitiates Coverage OnOverweight
Aug 2017Evercore ISI GroupInitiates Coverage OnIn-Line
Aug 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Reiteration Analyst Ratings Movers Trading Ideas Best of Benzinga

 

Related Articles (CELG + BLUE)

View Comments and Join the Discussion!
Loading...
Loading...